MEDICURE INC Annual Report - How They Did This Year

I’ve put together this guide to help you understand Medicure Inc.’s performance over the past year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Medicure is a Canadian pharmaceutical company focused on the U.S. market. They operate in two main areas:

• Drug Sales: They market heart medications. Their main product is Aggrastat, used in hospitals for heart attacks. They also sell Zypitamag, a statin used to treat high cholesterol.
• Pharmacy Services: Medicure runs a direct-to-consumer pharmacy business, including Marley Drug, Gateway Pharmacy, and West Olympia Pharmacy. These pharmacies sell medications directly to patients, bypassing traditional insurance-heavy distribution channels.

2. Financial performance and health

Medicure is currently in a transitional phase. Their main heart drug, Aggrastat, lost patent protection in 2023, leading to generic competition that has pressured both pricing and sales volume. Zypitamag also faces competition from lower-cost generic statins.

The company is managing financial obligations related to the U.S. "Inflation Reduction Act" (IRA), which imposes penalties if drug price increases exceed the rate of inflation. Medicure has recorded these penalties as liabilities and is currently engaging with government authorities regarding these costs.

3. Major wins and challenges

• Strategic Expansion: The acquisition of Gateway and West Olympia pharmacies is a core part of the company's strategy to control more of their business. By owning these pharmacies, they aim to lower shipping costs and build direct relationships with patients, which is intended to improve profit margins by controlling the supply chain.
• Global Operations: The company operates across Canada, the U.S., Barbados, and Ireland. They utilize specific tax structures to manage these international operations, making their bottom line sensitive to changes in global tax laws.

4. Key risks to watch

• Stock Volatility: Medicure’s share price has traded between CDN$0.63 and CDN$1.43 over the past year. Due to lower trading volume, the stock can experience significant price swings, which may impact your ability to enter or exit a position at a specific price.
• Dilution: The company has over 10 million shares outstanding, and this number is subject to change. The exercise of employee stock options or the issuance of new shares to raise capital could reduce your individual ownership percentage.
• No Dividends: Medicure does not pay dividends and intends to reinvest all profits into research and expansion. There is no guarantee that this strategy will result in future profitability or share price appreciation.
• Supply Chain Dependency: Medicure does not own its manufacturing facilities and relies on third-party partners. Any quality control issues or supply chain disruptions at these partner sites could directly impact the company's ability to fulfill orders and generate revenue.

Final Thought for Investors: Medicure is currently betting on a shift toward a direct-to-consumer pharmacy model to offset the decline of their legacy heart medications. When considering an investment, weigh whether you believe their pharmacy acquisitions can successfully replace the revenue lost from their aging drug patents. Because of the stock's volatility and the company's reliance on third-party manufacturers, it is important to consider if this level of risk aligns with your personal investment strategy.